summary Chronic pain has been identified as an important issue related to various rheumatic diseases. At the time of a major government spending review, it is appropriate to discuss the pain characterising rheumatic diseases and its related costs. It is clearly essential for healthcare authorities to rationalise their policies on the basis of the increasing expectations of the users of healthcare services while simultaneously balancing their books. There are few published studies concerning the costs of pain of any kind, and the same is true of the costs of the chronic pain associated with diseases such as rheumatoid arthritis, osteoarthritis, and fibromyalgia.
n INTRODUCTION C hronic pain (CP) is a frequent healthcare problem worldwide and the main reason for patients seeking medical advice (1) . It affects a large proportion of the inhabitants of the USA, where its prevalence is much higher than that of other conditions having a major social impact: back pain is the main cause of disability among Americans aged <45 years, and the latest statistics show that it affects about 26 million aged 20-64 years (2) . About 10 million people in the UK suffer from various forms of pain that have serious consequences on their quality of life and working activities. The National Rheumatoid Arthritis Society estimates that about 9.4 million working days are lost because of rheumatoid arthritis (RA), and 4.9 million because of back pain (3) . Pain in rheumatic disease (RD) (particularly chronic pain) has been identified as an important issue by the National Health Plan 2011-2013 of the Italian Ministry of Health (4, 5) . It is considered a disease that has its own nosographic dignity. Furthermore pain measurements and further information required by medical and healthcare personnel in order to improve the patients' quality of life also involves ethical aspects that have not yet been considered (6) (8, 9) . As is happening in other economically stronger European and non-European countries, in Italy the National Health Service is going through a major economic and financial crisis that is mainly due to a reduction in funding. It was established in 1978 during a period of relative economic prosperity, inspired by the principle of solidarity, and mainly funded by the population, but it is now struggling to find sustainable means of balancing the books, reducing the national budget, and reorganizing its structure without affecting the principles that inspired its creation (10) . As in the rest of the world, RDs in Italy have a social impact that is greater than that of many other diseases because of the high costs involved, which can be divided into three main groups: 1. Direct costs, such as the cost of drugs, diagnostic examinations, care and hospitalization, and also private consultations; 2. Indirect costs, such as lost work days or unemployment due to the disease, termination of contracts given the impossibility of working, transport to hospital and/or visits in private practices (and the possible lost work day by anyone accompanying the patient), pushing patients to work even when their job performance is serious affected because their physical condition; 3. Intangible costs arising for instance from significant changes in the quality of life and social habits (e.g. those relating to interpersonal relationships, or severe difficulties in pursuing a hobby). The first two groups have measurable parameters, although their calculation is not easy because of the many variables involved, whereas the costs in the third group can hardly be measured at all, and remain a matter of discussion between health authorities and patients. The negative impact of RDs on the patients' quality of life and working activity has been examined in a recent study conducted in six European countries (Belgium, Bulgaria, Ireland, Portugal, Spain and UK) (11) .
n COSTS OF PAIN IN OSTEOARTHRITIS
Pain is the main symptom of RDs: the pain related to osteoarthritis (OA) affects 10% of the Italian population with a prevalence of 7,129,842 cases, in particular in female sex (12) . Colombo et al. investigated the cost of acute and chronic pain in a prospective, observational study of the costs and the changes in the quality of life (QoL) associated with acute and chronic pain management in Italy that involved patients affected by chronic benign pain due to hip or knee OA, generalized OA, low back pain, a non-surgical hernia, slipped disc or shoulder periarthritis (13) . The patients had experienced pain symptoms for at least six months before the start of the study. Various questionnaires were used to investigate the description of pain, healthcare use before and after enrolment, and the willingness to pay for therapy. A previous study by the Italian Fibromyalgia Network showed that a high degree of disability and the number of pathologies associated with FM could significantly increase the direct and indirect costs of FMrelated pain management, whereas an early diagnosis reduced the use of economic resources for drugs, medical appointments and diagnostic investigations (18) .
n COSTS OF THE DRUGS USED FOR TREATING PAIN IN RHEUMATIC DISEASES
The OsMeD report of AIFA (Italian Drug Agency, Agenzia Italiana del Farmaco) Use of drugs in Italy as of September 2012 refers to the use of all types of drugs in hospitals. The cost for drugs used to treat patients with conditions affecting the musculoskeletal system, which represent the eighth largest drug category in the public budget, amounted to € 442 million (7.3 per capita). These costs are mainly associated with the so-called therapeutic drug assistance (6.3 per capita), whereas the purchase of drugs by the public health facilities was much less significant (1.0 per capita). With respect to the national healthcare system, the expenditure for drugs to treat musculoskeletal disorders decreased by 9.0% against 2011. This decline is due to the combination of a reduction in consumption (-4.3%), in prices (-5.4%) and a positive mix effect (+0.5%). Data shows that the purchase of these drugs by healthcare facilities is substantially stable if compared with 2011 (+0.06%), while consumption by the general population is increasing (+6.6%). The most widely used drug categories by the national healthcare service were anti-inflammatory NSAIDs and COXIBs, followed by biphosponates. global costs (visits, diagnostic examinations, drugs, etc.), however Italy seems to be in a good position in terms of time to diagnosis. Indirect costs also include costs due to side effects. An observational study presented by J. Goldstein in San Diego on the occasion of the Digestive Disease Week made use of an administrative database of 15 million people, 97% of whom were covered by commercial insurance policies. The analysis involved 1800 patients (2/3 female) with an average of 60 years, who were prescribed NSAIDs for 90 days because of OA. During the following 12 months, anemic patients were more likely to use healthcare resources (drugs, visits and diagnostic investigations) with an average cost of $ 42,368 against an average of $ 22,583 in a control group of patients who used NSAIDs but did not experience any significant change in hemoglobin levels (P<0.0001) (22) . 
